Treosulfan

CHEMBL455186 Phase 4 Disetujui Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

278.3 g/mol

LogP

-2.2

Phase

4

Treosulfan is a bifunctional alkylating agent and pro-drug that is spontaneously converted at physiological pH to a diepoxide form that cross-links DNA strands, inhibiting DNA replication and inducing apoptosis in rapidly dividing cells. It is used as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation in adults and children with hematologic malignancies including leukemia and lymphoma, offering myeloablative and immunosuppressive effects with a potentially more favorable toxicity profile than busulfan. Its activity in myeloid and lymphoid malignancies with reduced organ toxicity compared to classic conditioning agents represents a clinical advantage.

Berat Molekul

278,3000 g/mol

LogP

-2,20

TPSA

144,00 Å²

Lipinski RO5

Lulus

Area Terapeutik

Ovarian Cancer Non-Small Cell Lung Cancer Melanoma Lymphoma Prostate Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Struktur 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O

InChI

InChI=1S/C6H14O8S2/c1-15(9,10)13-3-5(7)6(8)4-14-16(2,11)12/h5-8H,3-4H2,1-2H3/t5-,6-/m0/s1

Molecular Formula

C6H14O8S2

HBD / HBA

2 / 8

Ikatan yang Dapat Dirotasi

7

Atom Berat

16

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

Treosulfan is a bifunctional alkylating agent and pro-drug that is spontaneously converted at physiological pH to a diepoxide form that cross-links DNA strands, inhibiting DNA replication and inducing apoptosis in rapidly dividing cells. It is used as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation in adults and children with hematologic malignancies including leukemia and lymphoma, offering myeloablative and immunosuppressive effects with a potentially more favorable toxicity profile than busulfan. Its activity in myeloid and lymphoid malignancies with …

Yes, Treosulfan is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL455186. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 9882105. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Mencari informasi yang ramah bagi pasien?

Treosulfan di PillFYI

Struktur

Data Cepat

Rumus: C6H14O8S2
Sinonim: 1

Tautan Eksternal

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.